REC610 is intended to prevent shingles in adults aged 40 years and above. Credit: aslysun / Shutterstock.com.

The Chinese National Medical Products Administration (NMPA) has accepted the clinical trial application from Jiangsu Recbio Technology for the REC610 shingles vaccine.

The regulator granted a notice of acceptance for analysing the new adjuvanted recombinant vaccine in clinical trials.

Related Company Profiles

View all

Recbio can begin the trials within 60 days from application acceptance, as per the filed plan. The trial commencement is contingent on receiving no negative or doubtful remarks from the NMPA’s Center for Drug Evaluation.

The prospective, double-blind, randomised, parallel, controlled Phase I trial of the vaccine will enrol 180 healthy adults age 40 years and above in Mainland China.

It will assess the tolerability, safety, and initial immunogenicity of REC610.

Intended for shingles prevention in adults aged 40 years and above, the vaccine comprises a new adjuvant of the company, BFA01.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The vaccine was demonstrated to have favourable immunogenicity and could elicit greater levels of gE antigen-specific CD4+T cell responses and IgG antibodies in preclinical studies.

It was also said to have an immune response that was not inferior to Shingrix, a controlled vaccine.

In February 2023, Recbio launched a first-in-human, active-controlled, GSK Shingrix trial of REC610 in the Philippines.  

All of the participants in the Philippines trial concluded the follow-up studies after 30 days of receiving two vaccine doses.

A viral infectious disease, shingles can adversely impact the patients’ quality of life, and is particularly harmful to elderly individuals.